Disease · MONDO_0001442

dysthymic disorder

6 sourcesdiseases-2026-09-18-0.1.0

Cite this record

ConductScience Library. dysthymic disorder. Diseases, record MONDO_0001442. Release diseases-2026-09-18-0.1.0, 18 Sept 2026. https://conductscience.org/library/diseases/MONDO_0001442

On this page

Disease

Names and IDs as Open Targets gives them. Its IDs in MeSH, Orphanet, the Disease Ontology and the NCI Thesaurus are those Open Targets states for it.

Name: dysthymic disorder; Open Targets
Open Targets ID: MONDO_0001442; Open Targets
Other names: Persistent depressive disorder, dysthymia, persistent mood; Open Targets
Disease Ontology: DOID:12139; Disease Ontology
MeSH: D019263; MeSH
NCI Thesaurus: C34562; NCI Thesaurus
Highest stage of its drugs: Phase 3, for 2 of its 12 drugs, from ClinicalTrials.gov; Open Targets

Drugs12

The drugs Open Targets' clinical reports study for the disease, the highest stage first, then the most trial reports. The stage is Open Targets', the highest any of its sources reports for the pair, and each row names the sources that report it.

Drug	ChEMBL ID	Type	Open Targets' stage	Stage reported by	Reports	Of them trials	Trials shown here	Source
PRAMIPEXOLE	CHEMBL301265	Small molecule	Phase 3	ClinicalTrials.gov	1	1	1	Drugs and targets
SERTRALINE	CHEMBL809	Small molecule	Phase 3	ClinicalTrials.gov	1	1	1	Drugs and targets
ATICAPRANT	CHEMBL1921847	Small molecule	Phase 2	ClinicalTrials.gov	1	1	1	Drugs and targets
DESIPRAMINE	CHEMBL72	Small molecule	Phase 2	ClinicalTrials.gov	1	1	1	Drugs and targets
EZOGABINE	CHEMBL41355	Small molecule	Phase 2	ClinicalTrials.gov	1	1	1	Drugs and targets
PRASTERONE	CHEMBL90593	Small molecule	Phase 2	ClinicalTrials.gov	1	1	1	Drugs and targets
PSILOCYBIN	CHEMBL194378	Small molecule	Phase 2	ClinicalTrials.gov	1	1	1	Drugs and targets
(+/-)NICOTINE	CHEMBL440464	Small molecule	Phase 1/2	ClinicalTrials.gov	1	1	1	Drugs and targets
NICOTINE	CHEMBL3	Small molecule	Phase 1/2	ClinicalTrials.gov	1	1	1	Drugs and targets
ESKETAMINE	CHEMBL395091	Small molecule	Phase 1	ClinicalTrials.gov	1	1	1	Drugs and targets

1 to 10 of 12

See all 12 drugs

Targets21

The targets ChEMBL's mechanism records give for the disease's drugs, through Open Targets, the most drugs first. A mechanism record says what a drug acts on, not that the target causes the disease.

Target	Protein	Its drugs that act on it	Mechanisms	Highest stage of those drugs	Gene in Genes	Source
SLC6A2	Sodium-dependent noradrenaline transporter	3	Norepinephrine transporter inhibitor	Phase 2	https://conductscience.org/library/genes/6530	Drugs and targets
SLC6A4	Sodium-dependent serotonin transporter	3	Serotonin transporter inhibitor	Phase 3	https://conductscience.org/library/genes/6532	Drugs and targets
CHRNA4	Neuronal acetylcholine receptor; alpha4/beta2	1	Neuronal acetylcholine receptor; alpha4/beta2 agonist	Phase 1/2	https://conductscience.org/library/genes/1137	Drugs and targets
CHRNB2	Neuronal acetylcholine receptor; alpha4/beta2	1	Neuronal acetylcholine receptor; alpha4/beta2 agonist	Phase 1/2	https://conductscience.org/library/genes/1141	Drugs and targets
DRD2	D2-like dopamine receptor	1	D2-like dopamine receptor agonist	Phase 3	https://conductscience.org/library/genes/1813	Drugs and targets
DRD3	D2-like dopamine receptor	1	D2-like dopamine receptor agonist	Phase 3	https://conductscience.org/library/genes/1814	Drugs and targets
DRD4	D2-like dopamine receptor	1	D2-like dopamine receptor agonist	Phase 3	https://conductscience.org/library/genes/1815	Drugs and targets
GRIN1	Glutamate [NMDA] receptor	1	Glutamate [NMDA] receptor negative allosteric modulator	Phase 1	https://conductscience.org/library/genes/2902	Drugs and targets
GRIN2A	Glutamate [NMDA] receptor	1	Glutamate [NMDA] receptor negative allosteric modulator	Phase 1	https://conductscience.org/library/genes/2903	Drugs and targets
GRIN2B	Glutamate [NMDA] receptor	1	Glutamate [NMDA] receptor negative allosteric modulator	Phase 1	https://conductscience.org/library/genes/2904	Drugs and targets

1 to 10 of 21

See all 21 targets

Trials11

Trials an Open Targets clinical report links to the disease, posted results first, then the largest. A trial is shown when the release's checks confirm its link to the disease and Drugs and targets shows its link to one of the disease's drugs.

Trial	Title	Phase	Participants	Results first posted	Conditions	Drugs	Linked by	Source
NCT02358343	A Trial of Sertraline vs. CBT for End-stage Renal Disease Patients With Depression {ASCEND}	Phase 3	184	2019-07-23	Depression, End Stage Renal Disease	SERTRALINE	Its record names the disease	ClinicalTrials.gov
NCT02218736	Fast-Fail Trials in Mood and Anxiety Spectrum Disorders; Kappa Opioid Receptor Phase 2a	Phase 2	163	2019-01-08	ANXIETY DISORDERS (or Anxiety and Phobic Neuroses)	ATICAPRANT	Its record names the disease	ClinicalTrials.gov
NCT03043560	Study to Treat Major Depressive Disorder With a New Medication	Phase 2	45	2020-10-23	Depressive Disorder, Anhedonia	EZOGABINE	Its record names the disease	ClinicalTrials.gov
NCT00000271	New Approaches to Cocaine Abuse Medications (A) - 6	Phase 2	111		Cocaine-Related Disorders, Substance-Related Disorders	DESIPRAMINE	Its record names the disease	ClinicalTrials.gov
NCT00494728	Smoking Cessation for Depressed Smokers	Phase 1/2	91		Smoking, Depression	(+/-)NICOTINE, NICOTINE	Its record names the disease	ClinicalTrials.gov
NCT00001487	Treatment of Mid-Life-Related Mood Disorders	Phase 2	60		Depressive Disorder, Mood Disorder	PRASTERONE	Its record names the disease	ClinicalTrials.gov
NCT05825235	Long-term Efficacy of Pramipexole in Anhedonic Depression	Phase 3	55		Anhedonia, Depression	PRAMIPEXOLE	Its record names the disease	ClinicalTrials.gov
NCT06072898	A Randomized Neuroimaging Trial of Psilocybin in Depression	Phase 2	50		Depressive Disorder, Major Depressive Disorder	PSILOCYBIN	Its record names the disease	ClinicalTrials.gov
NCT01948895	Desvenlafaxine Monotherapy in Dysthymia	Not applicable	30		Dysthymic Disorder	DESVENLAFAXINE	Its record names the disease	ClinicalTrials.gov
NCT02919579	A Study to Evaluate the Effects of a Single-Dose and Repeat-Administration of Intranasal Esketamine on On-Road Driving in Participants With Major Depressive Disorder	Phase 1	27		Depressive Disorder, Major	ESKETAMINE	Its record names the disease	ClinicalTrials.gov

1 to 10 of 11

See all 11 trials

Comparisons in its trials8

Comparisons Trial comparisons calculated in the trials shown here, most participants first. A comparison in one of these trials does not always compare a treatment for the disease, so read the two groups.

Comparison	Group 1, with the outcome	Group 2, with the outcome	Participants	Trial	Source
Engagement Interview vs Control Visit: Number of Participants Who Accepted Depression Treatment	70 of 86	70 of 86	172	NCT02358343	Trial comparisons
Engagement Interview vs Control Visit: Number of Participants Who Initiated Depression Treatment	57 of 86	54 of 84	170	NCT02358343	Trial comparisons
Cognitive Behavioral Therapy vs Antidepressant Drug Therapy: deaths from any cause	2 of 60	0 of 60	120	NCT02358343	Trial comparisons
Cognitive Behavioral Therapy vs Antidepressant Drug Therapy: serious adverse events	11 of 60	14 of 60	120	NCT02358343	Trial comparisons
CERC-501 vs Placebo: deaths from any cause	0 of 45	0 of 44	89	NCT02218736	Trial comparisons
CERC-501 vs Placebo: serious adverse events	0 of 45	0 of 44	89	NCT02218736	Trial comparisons
Ezogabine vs Placebo: deaths from any cause	0 of 21	0 of 24	45	NCT03043560	Trial comparisons
Ezogabine vs Placebo: serious adverse events	0 of 21	0 of 24	45	NCT03043560	Trial comparisons

Papers from its trials10

The papers the trials shown here list on ClinicalTrials.gov as their results (RESULT) or as drawn from them (DERIVED), results first, newest first.

PMID	Listed as	Trials listing it	Source
17503986	RESULT	1	PubMed
15913920	RESULT	1	PubMed
42286321	DERIVED	1	PubMed
38956594	DERIVED	1	PubMed
38035737	DERIVED	1	PubMed
37651553	DERIVED	1	PubMed
35212235	DERIVED	1	PubMed
33653118	DERIVED	1	PubMed
30802897	DERIVED	1	PubMed
26621218	DERIVED	1	PubMed

Data dates

The date of each source this release read.

Open Targets: 2026-09-18; Open Targets
Drug links and their checks, from Drugs and targets: 2026-09-18; Drugs and targets
ClinicalTrials.gov, from Trials: 2026-11-12; Trials
Comparisons, from Trial comparisons: 2026-03-23; Trial comparisons
PubMed, for the checks: 2026-11-06; PubMed
MeSH, for the checks: 2026-11-10; MeSH

Sources 6

ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
ChEMBL, through Open TargetsCC BY-SA 3.0
ClinicalTrials.govNo license stated
NLM's MeSHNLM's terms
Open TargetsCC0 1.0
PubMedNLM's terms

Each source's terms

ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
ClinicalTrials.govnone stated
NLM's MeSHNLM's
Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
PubMedNLM's terms

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this disease from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/diseases/v1/MONDO_0001442

GET https://conductscience.org/api/diseases/v1/MONDO_0001442/targets?page=2

API reference For AI assistants